Silencing heme oxygenase-1 increases the sensitivity of ABC-DLBCL cells to histone deacetylase inhibitor in vitro and in vivo.

In conclusion, HO-1 is a potential therapeutic target of DLBCL. The findings provide a valuable preclinical evidence for sensitizing DLBCL patients with poor prognosis to histone deacetylase inhibitors.
PMID: 28775232 [PubMed - as supplied by publisher]

Source: Oncotarget - August 6, 2017 Category: Cancer & Oncology Tags: Oncotarget Source Type: research